Brisbane-based Vaxxas has raised ~A$90m (A$49.22m Series D equity plus a A$40m debt facility), extending its cash runway into the second half of 2027, and triggering a leadership hand-off as founding CEO David Hoey moves into a strategic advisor role while the board completes a global CEO search. The round was led by SPRIM Global Investments with participation from new backer LGT Crestone and existing investors OneVentures and Brandon Capital–Hostplus. The company says proceeds will fund late-stage readiness for its high-density microarray patch (HD-MAP) platform, including semi-automated manufacturing lines.
Why this matters now
Vaccine delivery has barely changed in a century: liquid doses,
